• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物研发的下一个前沿领域:外部对照臂与丰富临床试验数据的创新工具。

The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data.

作者信息

Zou Kelly H, Vigna Chelsea, Talwai Aniketh, Jain Rahul, Galaznik Aaron, Berger Marc L, Li Jim Z

机构信息

Viatris, Canonsburg, PA, USA.

Medidata Solutions, a Dassault Systèmes Company, Boston, MA, USA.

出版信息

Ther Innov Regul Sci. 2024 May;58(3):443-455. doi: 10.1007/s43441-024-00627-4. Epub 2024 Mar 25.

DOI:10.1007/s43441-024-00627-4
PMID:38528279
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11043157/
Abstract

Conducting clinical trials (CTs) has become increasingly costly and complex in terms of designing and operationalizing. These challenges exist in running CTs on novel therapies, particularly in oncology and rare diseases, where CTs increasingly target narrower patient groups. In this study, we describe external control arms (ECA) and other relevant tools, such as virtualization and decentralized clinical trials (DCTs), and the ability to follow the clinical trial subjects in the real world using tokenization. ECAs are typically constructed by identifying appropriate external sources of data, then by cleaning and standardizing it to create an analysis-ready data file, and finally, by matching subjects in the external data with the subjects in the CT of interest. In addition, ECA tools also include subject-level meta-analysis and simulated subjects' data for analyses. By implementing the recent advances in digital health technologies and devices, virtualization, and DCTs, realigning of CTs from site-centric designs to virtual, decentralized, and patient-centric designs can be done, which reduces the patient burden to participate in the CTs and encourages diversity. Tokenization technology allows linking the CT data with real-world data (RWD), creating more comprehensive and longitudinal outcome measures. These tools provide robust ways to enrich the CT data for informed decision-making, reduce the burden on subjects and costs of trial operations, and augment the insights gained for the CT data.

摘要

就设计和实施而言,开展临床试验(CTs)的成本越来越高,难度也越来越大。在开展针对新型疗法的临床试验时,这些挑战尤为突出,特别是在肿瘤学和罕见病领域,临床试验越来越多地针对更狭窄的患者群体。在本研究中,我们描述了外部对照臂(ECA)以及其他相关工具,如虚拟化和去中心化临床试验(DCTs),以及使用令牌化技术在现实世界中跟踪临床试验受试者的能力。ECA通常通过识别合适的外部数据源来构建,然后对其进行清理和标准化,以创建一个可供分析的数据文件,最后,将外部数据中的受试者与感兴趣的CT中的受试者进行匹配。此外,ECA工具还包括受试者层面的荟萃分析和用于分析的模拟受试者数据。通过应用数字健康技术和设备、虚拟化以及DCTs方面的最新进展,可以将CTs从以站点为中心的设计重新调整为虚拟、去中心化和以患者为中心的设计,这减轻了患者参与CTs的负担,并鼓励了多样性。令牌化技术允许将CT数据与真实世界数据(RWD)相链接,从而创建更全面和纵向的结果测量。这些工具提供了强大的方法来丰富CT数据,以便做出明智的决策,减轻受试者的负担和试验运营成本,并增强从CT数据中获得的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a3/11043157/3ab5286bddd7/43441_2024_627_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a3/11043157/3ab5286bddd7/43441_2024_627_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a2a3/11043157/3ab5286bddd7/43441_2024_627_Fig1_HTML.jpg

相似文献

1
The Next Horizon of Drug Development: External Control Arms and Innovative Tools to Enrich Clinical Trial Data.药物研发的下一个前沿领域:外部对照臂与丰富临床试验数据的创新工具。
Ther Innov Regul Sci. 2024 May;58(3):443-455. doi: 10.1007/s43441-024-00627-4. Epub 2024 Mar 25.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
4
Healthcare workers' informal uses of mobile phones and other mobile devices to support their work: a qualitative evidence synthesis.医护人员非正规使用手机和其他移动设备来支持工作:定性证据综合评价。
Cochrane Database Syst Rev. 2024 Aug 27;8(8):CD015705. doi: 10.1002/14651858.CD015705.pub2.
5
Anterior Approach Total Ankle Arthroplasty with Patient-Specific Cut Guides.使用患者特异性截骨导向器的前路全踝关节置换术。
JBJS Essent Surg Tech. 2025 Aug 15;15(3). doi: 10.2106/JBJS.ST.23.00027. eCollection 2025 Jul-Sep.
6
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.改善消费者安全有效用药的干预措施:系统评价概述
Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3.
7
Comparison of self-administered survey questionnaire responses collected using mobile apps versus other methods.使用移动应用程序与其他方法收集的自我管理调查问卷回复的比较。
Cochrane Database Syst Rev. 2015 Jul 27;2015(7):MR000042. doi: 10.1002/14651858.MR000042.pub2.
8
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
9
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
10
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理:一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.

引用本文的文献

1
Remdesivir associated with reduced mortality in hospitalized COVID-19 patients: treatment effectiveness using real-world data and natural language processing.瑞德西韦与住院COVID-19患者死亡率降低相关:利用真实世界数据和自然语言处理的治疗效果
BMC Infect Dis. 2025 Apr 12;25(1):513. doi: 10.1186/s12879-025-10817-6.
2
Synthetic Data in Healthcare and Drug Development: Definitions, Regulatory Frameworks, Issues.医疗保健与药物研发中的合成数据:定义、监管框架、问题
CPT Pharmacometrics Syst Pharmacol. 2025 May;14(5):840-852. doi: 10.1002/psp4.70021. Epub 2025 Apr 7.
3
Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union.

本文引用的文献

1
Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials.评估观察性方法和真实世界数据在模拟正在进行的随机对照试验中的应用。
Clin Trials. 2023 Dec;20(6):689-698. doi: 10.1177/17407745231193137. Epub 2023 Aug 17.
2
Simulants: Synthetic Clinical Trial Data via Subject-Level Privacy-Preserving Synthesis.模拟物:通过基于受试者的隐私保护综合方法生成的合成临床试验数据。
AMIA Annu Symp Proc. 2023 Apr 29;2022:231-240. eCollection 2022.
3
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.
美国和欧盟医疗保健领域的真实世界数据与真实世界证据
Bioengineering (Basel). 2024 Aug 2;11(8):784. doi: 10.3390/bioengineering11080784.
历史性临床试验外部对照臂在随机试验前提供了可操作的 GEN-1 疗效估计。
JCO Clin Cancer Inform. 2023 Jan;7:e2200103. doi: 10.1200/CCI.22.00103.
4
Enhanced Patient-Centricity: How the Biopharmaceutical Industry Is Optimizing Patient Care through AI/ML/DL.增强以患者为中心:生物制药行业如何通过人工智能/机器学习/深度学习优化患者护理。
Healthcare (Basel). 2022 Oct 11;10(10):1997. doi: 10.3390/healthcare10101997.
5
Retrieved-Dropout-Based multiple imputation for time-to-event data in cardiovascular outcome trials.心血管结局试验中基于检索式失访的生存数据多重填补法
J Biopharm Stat. 2023 Mar;33(2):234-252. doi: 10.1080/10543406.2022.2118763. Epub 2022 Sep 19.
6
Considerations for Conducting Bring Your Own "Device" (BYOD) Clinical Studies.开展自带“设备”(BYOD)临床研究的注意事项。
Digit Biomark. 2022 Jul 4;6(2):47-60. doi: 10.1159/000525080. eCollection 2022 May-Aug.
7
Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan.从监管科学视角看日本基于真实世界数据的监管审批
Front Med (Lausanne). 2022 Apr 15;9:864960. doi: 10.3389/fmed.2022.864960. eCollection 2022.
8
Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development.真实世界数据在肿瘤临床试验药物研发外部对照组中的应用。
Front Oncol. 2022 Jan 6;11:695936. doi: 10.3389/fonc.2021.695936. eCollection 2021.
9
External control arms in oncology: current use and future directions.肿瘤学中的外部对照臂:当前应用与未来方向。
Ann Oncol. 2022 Apr;33(4):376-383. doi: 10.1016/j.annonc.2021.12.015. Epub 2022 Jan 10.
10
Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer.探索利用患者层面数据创建外部对照臂的潜力:非小细胞肺癌的案例研究
J Biopharm Stat. 2022 Jan 2;32(1):204-218. doi: 10.1080/10543406.2021.2011901. Epub 2022 Jan 5.